Generali Asset Management SPA SGR Sells 5,031 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Generali Asset Management reduced its stake in Vertex by 21.3%, selling 5,031 shares and leaving 18,538 shares valued at about $8.404 million per its latest SEC filing.
• Insider selling has been notable—81,853 shares sold in the last three months, including EVP Amit Sachdev's 58,613‑share sale (~$27.5M)—which could weigh on investor sentiment despite some trades under 10b5‑1 plans.
• Vertex beat Q1 EPS ($4.47 vs. $4.24 est.) and reiterated full‑year 2026 revenue guidance of ~$13.0–13.1B; analysts' consensus rating is a "Moderate Buy" with a $555.17 average price target.

Generali Asset Management SPA SGR decreased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 21.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 18,538 shares of the pharmaceutical company's stock after selling 5,031 shares during the period. Generali Asset Management SPA SGR's holdings in Vertex Pharmaceuticals were worth $8,404,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of VRTX. Brighton Jones LLC increased its stake in shares of Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company's stock valued at $1,783,000 after purchasing an additional 579 shares during the last quarter. Gamco Investors INC. ET AL bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $228,000. NewEdge Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 9.0% in the 2nd quarter. NewEdge Advisors LLC now owns 11,929 shares of the pharmaceutical company's stock valued at $5,311,000 after purchasing an additional 986 shares during the last quarter. ICW Investment Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 5.0% in the 2nd quarter. ICW Investment Advisors LLC now owns 604 shares of the pharmaceutical company's stock valued at $269,000 after purchasing an additional 29 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its stake in shares of Vertex Pharmaceuticals by 26.3% in the 2nd quarter. Diversify Advisory Services LLC now owns 7,291 shares of the pharmaceutical company's stock valued at $3,246,000 after purchasing an additional 1,518 shares during the last quarter. Institutional investors own 90.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on VRTX shares. Jefferies Financial Group initiated coverage on Vertex Pharmaceuticals in a research note on Tuesday, March 10th. They issued a "buy" rating and a $580.00 price target on the stock. Scotiabank raised their price objective on Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an "outperform" rating in a report on Friday, February 13th. UBS Group raised their price objective on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the company a "buy" rating in a report on Monday, January 26th. HC Wainwright raised their price objective on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a "buy" rating in a report on Tuesday, March 10th. Finally, Wall Street Zen downgraded Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $555.17.

Insider Activity

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,329 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $481.79, for a total transaction of $1,122,088.91. Following the transaction, the chief marketing officer directly owned 35,405 shares of the company's stock, valued at approximately $17,057,774.95. The trade was a 6.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Amit Sachdev sold 58,613 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $468.83, for a total value of $27,479,532.79. Following the transaction, the executive vice president directly owned 58,934 shares in the company, valued at $27,630,027.22. The trade was a 49.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 81,853 shares of company stock worth $38,479,135. 0.20% of the stock is owned by corporate insiders.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q1 beat on EPS and showed product revenue growth driven by new CF and recently launched therapies, supporting the company’s longer‑term thesis. Business Wire: Vertex Reports First Quarter 2026 Financial Results
• Positive Sentiment: Germany signed a reimbursement agreement for CASGEVY (exagamglogene autotemcel), securing access for eligible SCD and transfusion‑dependent beta thalassemia patients — a meaningful commercial milestone for Vertex’s gene‑editing franchise. Business Wire: CASGEVY Reimbursement in Germany
• Positive Sentiment: Recognition from the National Kidney Foundation (2026 Kidney Biotech Innovation Award) reinforces Vertex’s credibility in expanding indications beyond CF. Yahoo: NKF Honors Vertex
• Neutral Sentiment: Management reiterated full‑year 2026 revenue guidance (~$13.0B–$13.1B). That stability removes a down‑side surprise but offered no clear upside catalyst, so analysts adjusted models and some trimmed price targets. Benzinga: Analysts Revise Forecasts After Q1
• Neutral Sentiment: Minor insider activity included a small option acquisition by Michel Lagarde (~$9k) — limited signal for the broader market. Benzinga: Michel Lagarde Option Purchase
• Negative Sentiment: Insider sales were reported this week (including Director Sangeeta Bhatia and EVP Joy Liu). Trades occurred under 10b5‑1 plans, but active selling can weigh on sentiment and contributed to selling pressure. SEC Form 4 (Sangeeta Bhatia)
• Negative Sentiment: Market reaction was tepid — despite the EPS beat some investors took profits and several outlets flagged that the results leave near‑term visibility mixed; commentary and calls for a bolder M&A strategy added to cautious sentiment. Seeking Alpha: Q1 Earnings Review

Vertex Pharmaceuticals Stock Down 0.6%

NASDAQ VRTX opened at $425.00 on Friday. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $507.92. The company has a market cap of $107.87 billion, a price-to-earnings ratio of 25.21, a price-to-earnings-growth ratio of 1.85 and a beta of 0.30. The business's fifty day moving average is $450.45 and its 200 day moving average is $449.78.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.24 by $0.23. The firm had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The business's quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the previous year, the business earned $4.06 EPS. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.81 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.